NCT05921279 Understanding CARdiac Events in Breast Cancer
| NCT ID | NCT05921279 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National University of Ireland, Galway, Ireland |
| Condition | Breast Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2023-01-14 |
| Primary Completion | 2026-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2023-01-14 with a primary completion date of 2026-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In Ireland, over 3,000 patients are diagnosed with breast cancer annually, and 1 in 9 Irish women will be diagnosed with breast cancer in their lifetime. There is evidence that female breast cancer survivors are more likely to die of cardiovascular disease than their age-matched counterparts. This research is focused on evaluating pathways for identifying, managing, and overcoming side effects of cancer therapies that can negatively impact quality-of-life and overall outcomes for women during and after cancer treatment. The Cardio-oncology research team at GUH plan to capitalize on their expertise in both cancer care and cardiology to develop a care pathway for cancer patients who are at increased risk of developing heart disease.
Eligibility Criteria
Inclusion Criteria: * Women aged ≥ 18 years * Ability to read and understand English * Breast Cancer Stage I- III planned to receive systemic chemotherapy Exclusion Criteria: * Patients not for systemic chemotherapy with curative intent * Patients who are unable to co-operate with the study protocol * Patients who are unable to give informed consent
Contact & Investigator
Osama Soliman, MBBCh, PhD
PRINCIPAL INVESTIGATOR
NUIG
Frequently Asked Questions
Who can join the NCT05921279 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 90 Years, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05921279 currently recruiting?
Yes, NCT05921279 is actively recruiting participants. Contact the research team at osama.soliman@nuigalway.ie for enrollment information.
Where is the NCT05921279 trial being conducted?
This trial is being conducted at Galway, Ireland, Galway, Ireland, Mayo, Ireland, Sligo, Ireland.
Who is sponsoring the NCT05921279 clinical trial?
NCT05921279 is sponsored by National University of Ireland, Galway, Ireland. The principal investigator is Osama Soliman, MBBCh, PhD at NUIG. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.